Skip to content

US · NRXP · BIOTECHNOLOGY

NRx Pharmaceuticals, Inc. (NRXP) intrinsic value and stock valuation

$2.15as of 2026-11-21 · Mkt cap 52.81M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

NRx Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values NRXP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NRXP’s statements →

NRx Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Wilmington, DE 19801 nrxpharma.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$1.23M
20172025
Net income
-$-28.62M
20172025
Free cash flow
-$-14.11M
20172025
Total equity
-$-15.94M
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$1.23M$0.00$0.00$0.00$0.00
Operating income-$-16.22M-$-19.7M-$-27.59M-$-44.34M-$-95.2M
Net income-$-28.62M-$-25.13M-$-30.15M-$-39.75M-$-93.06M
EPSd-$-1.34M-$-2.39M-$-3.98M-$-604.38K-$-1.98M
Operating cash flow-$-14.11M-$-10.64M-$-21.66M-$-39.76M-$-37.7M
Capital expenditure$0.00$0.00-$0.00-$-10K-$-10K
Free cash flow-$-14.11M-$-10.64M-$-21.66M-$-39.77M-$-37.71M
Total assets$13M$3.65M$7.32M$25.8M$32.7M
Total debt$630K$6.58M$9.16M$10.5M$520K
Net debt-$-7.17M$5.13M$4.57M-$-9.53M-$-27.09M
Total equity-$-15.94M-$-23.22M-$-11.73M$7.41M$20.8M
Cash and short-term investments$7.8M$1.44M$4.59M$20.1M$27.6M
Income statement
20252024202320222021
Revenue$1.23M$0.00$0.00$0.00$0.00
Cost of revenue$510K$10K$10K$0.00$0.00
Gross profit$720K-$-10K-$-10K-$0.00-$0.00
Research and development expenses$3.78M$6.2M$13.4M$17M$20.3M
Selling, general and administrative expenses$13.1M$13.5M$14.2M$27.3M$74.9M
Other expenses$110K$0.00$0.00$0.00$0.00
Operating expenses$16.9M$19.7M$27.6M$44.3M$95.2M
Cost and expenses$17.5M$19.7M$27.6M$44.3M$95.2M
Interest income$10K$40K$490K$250K$0.00
Interest expense$670K$1.08M$120K$0.00$20K
Depreciation and amortization$140K$10K$10K$0.00$0.00
Ebitda-$-27.81M-$-24.04M-$-30.02M-$-39.75M-$-93.04M
Operating income-$-16.22M-$-19.7M-$-27.59M-$-44.34M-$-95.2M
Total other income/expenses, net-$-12.4M-$-5.42M-$-2.56M$4.58M$2.14M
Income before tax-$-28.62M-$-25.13M-$-30.15M-$-39.75M-$-93.06M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-28.62M-$-25.13M-$-30.15M-$-39.75M-$-93.06M
Weighted average shares outstanding$21.4M$10.5M$7.58M$65.8M$46.9M
Weighted average diluted shares outstanding$21.4M$10.5M$7.58M$65.8M$46.9M
Balance sheet
20252024202320222021
Cash and short-term investments$7.8M$1.44M$4.59M$20.1M$27.6M
Net receivables$160K$0.00$10K$10K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$8.89M$3.3M$6.88M$25.8M$32.7M
Property, plant and equipment, net$630K$0.00$0.00$0.00$0.00
Goodwill and intangible assets$2.72M$0.00$0.00$0.00$0.00
Long-term investments$400K$0.00$0.00$0.00$0.00
Total non-current assets$4.06M$350K$430K$20K$10K
Total assets$13M$3.65M$7.32M$25.8M$32.7M
Accounts payable$4.27M$4.13M$4.63M$2.08M$3.69M
Short-term debt$320K$1.57M$9.16M$7.7M$520K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$28.6M$21.9M$19.1M$15.6M$11.9M
Long-term debt$320K$5.01M$0.00$2.82M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$320K$5.01M$0.00$2.82M$0.00
Capital lease obligations$630K$0.00$0.00$0.00$0.00
Total liabilities$28.9M$26.9M$19.1M$18.4M$11.9M
Common stock$30K$10K$80K$70K$60K
Retained earnings-$-306.89M-$-278.27M-$-253.15M-$-223M-$-183.24M
Accumulated other comprehensive income (loss)$0.00$0.00-$0.00$0.00$0.00
Total equity-$-15.94M-$-23.22M-$-11.73M$7.41M$20.8M
Total investments$400K$0.00$0.00$0.00$0.00
Total debt$630K$6.58M$9.16M$10.5M$520K
Net debt-$-7.17M$5.13M$4.57M-$-9.53M-$-27.09M
Cash flow statement
20252024202320222021
Net income-$-28.62M-$-25.13M-$-30.15M-$-39.75M-$-93.06M
Depreciation and amortization$140K$10K$10K$0.00$0.00
Stock-based compensation$230K$490K$390K$3.63M$7.79M
Change in working capital$1.41M$5.29M$5.16M$700K-$-4.9M
Accounts receivable$50K$0.00$0.00$0.00$830K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$110K-$-5.22M$2.65M-$-1.61M-$-20K
Net cash provided by operating activities-$-14.11M-$-10.64M-$-21.66M-$-39.76M-$-37.7M
Investments in property, plant and equipment$0.00$0.00-$0.00-$-10K-$-10K
Acquisitions, net-$-2.38M$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-2.81M$0.00-$0.00-$-10K-$-10K
Common stock issued$19M$5.91M$8.12M$22.7M$37M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$23.3M$7.49M$6.2M$32.2M$63.5M
Net change in cash$6.35M-$-3.15M-$-15.46M-$-7.55M$25.8M
Cash at end of period$7.8M$1.44M$4.59M$20.1M$27.6M
Operating cash flow-$-14.11M-$-10.64M-$-21.66M-$-39.76M-$-37.7M
Capital expenditure$0.00$0.00-$0.00-$-10K-$-10K
Free cash flow-$-14.11M-$-10.64M-$-21.66M-$-39.77M-$-37.71M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About NRx Pharmaceuticals, Inc.

        NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.

        CEO
        Jonathan C. Javitt
        Employees
        29
        Beta
        2.19

        Explore

        Frequently asked questions

        What is the intrinsic value of NRx Pharmaceuticals, Inc. (NRXP)?

        InvestorsCraft does not currently publish an intrinsic value for NRXP. How the IC value is calculated.

        Is NRXP undervalued?

        InvestorsCraft does not publish an undervaluation signal for NRXP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.